Deep Breaths: Updates from CHEST

Living with severe asthma can mean hospital stays, repeated oral steroid courses, and a long search for the right care, with many eligible patients still facing delays in starting advanced therapies or struggling to stay on them. In this episode of Deep Breaths: Updates from CHEST, Dr. Diego Maselli talks with patient advocate Stephanie Fuller about her journey from uncontrolled asthma to starting biologic therapy. Together, they explore why having ongoing conversations built on knowing the whole patient can help improve outcomes for severe asthma patients. Dr. Diego Maselli is Professor and Chief of the Division of Pulmonary Diseases and Critical Care at UT Health in San Antonio.

This information is scientific and non-promotional in nature. This educational program was developed by CHEST in collaboration with and sponsored by GSK.

This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared decision-making conversations. Speakers will explore why many patients who qualify for low-dose CT scan screening are still not screened. Learn practice strategies to help close preventable gaps in care, including identifying risk during routine visits, addressing patient concerns, ordering appropriate screening, and ensuring follow-up for findings such as pulmonary nodules.

Part of the educational program Bridging Specialties®: Timely Diagnosis and Treatment for Refractory Chronic Cough, this activity explores emerging scientific insights and therapeutic advances shaping the management of refractory chronic cough (RCC). Despite appropriate evaluation and treatment of common etiologies, many patients continue to experience persistent cough consistent with cough hypersensitivity syndrome. Advances in understanding ATP–P2X3 signaling and neural mechanisms have reshaped the conceptual framework for RCC and informed the development of emerging therapies. This activity reviews the neurobiology of cough hypersensitivity, current management gaps, and the evolving therapeutic landscape. Clinicians will gain insight into mechanism-based care strategies and patient-centered counseling considerations in RCC management.

Part of the educational program Bridging Specialties®: Timely Diagnosis and Treatment for Refractory Chronic Cough, this activity examines the diagnostic challenges associated with refractory chronic cough (RCC) and the importance of coordinated, guideline-directed evaluation across specialties. RCC is frequently characterized by prolonged diagnostic delays, repeated empiric treatments, and fragmented care across specialties. Many patients experience months of persistent symptoms before a structured evaluation is implemented. This activity highlights practical strategies for applying a CHEST guideline-directed diagnostic pathway to improve efficiency, reduce unnecessary repetition, and support timely multidisciplinary coordination. Clinicians will gain tools to streamline evaluation and reduce patient burden.

COPD is increasingly recognized as a heterogeneous disease, and for a subset of patients, type 2 inflammation plays a meaningful role in exacerbation risk and treatment response. Given that, Drs. Stephanie Christenson and Diego Maselli come together to examine how insights into the pathobiology of type 2 inflammation can directly inform clinical decision making in COPD. Specifically, they discuss the practical use of blood eosinophil counts to phenotype patients, assess risk, and guide therapy selection within the context of GOLD 2025 and 2026 guidance. Dr. Christenson is an Associate Professor at the University of California San Francisco in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, and Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health in San Antonio.

This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

For patients with chronic obstructive pulmonary disease (COPD), exacerbations are early indicators of disease progression—not just isolated events. In this expert-led discussion, Drs. Ravi Kalhan and Meilan Han break down the latest GOLD updates, explain how to use eosinophil counts to guide treatment, and discuss when to consider adding biologic therapy. Dr. Kalhan is the Louis A. Simpson Professor of Pulmonary Medicine and Director of the Asthma and COPD Program at Northwestern Medicine in Chicago. Dr. Han is a Professor of Medicine and Chief of the Division of Pulmonary and Critical Care at the University of Michigan Health in Ann Arbor.

This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Subtle symptoms and overlooked risk factors can delay diagnosis of methamphetamine-associated pulmonary arterial hypertension (PAH), especially given regional differences in clinical practice and access to care. Dr. Rodolfo Estrada speaks with Drs. Steven Hollenberg and Dana Kay about improving clinical awareness, navigating treatment challenges, and understanding the value of collaborative, patient-centered care. Dr. Estrada is an Associate Professor of Internal Medicine in the Division of Pulmonary and Critical Care and the Director of the Pulmonary Hypertension Program at the University of Texas in San Antonio. Dr. Hollenberg is a Professor of Medicine at the Emory University School of Medicine and the Director of Cardiac Intensive Care at the Emory Heart and Vascular Institute in Atlanta. Dr. Kay is an Assistant Professor of Clinical Medicine in the Division of Pulmonary and Critical Care at the University of Cincinnati.

This program is produced in partnership with the American College of Chest Physicians and is sponsored by Actelion Pharmaceuticals US, Inc.

For further expert insight, view the on demand CHEST webinar on Methamphetamine-Associated Pulmonary Arterial Hypertension: VIEW NOW »

The 2025 European Society for Medical Oncology Congress and World Conference on Lung Cancer revealed significant updates in non-small cell lung cancer care. Learn more as Drs. Gerard Silvestri, Mariam Alexander, and Jessica Donington review new data on EGFR- and ROS1-targeted therapies, perioperative immunotherapy, and multidisciplinary strategies to expand resectability in stage III non-small cell lung cancer. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Alexander is an Assistant Professor of Medical Oncology at the Medical University of South Carolina. Dr. Donington is a Professor in Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago.

This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

From updated surveillance strategies to evolving biopsy techniques and treatment advances, recent findings presented at 2025 conferences are reshaping non-small cell lung cancer management. Dr. Gerard Silvestri speaks with Drs. Adam Fox and Anurag Singh to explore key data influencing diagnostic decisions, patient-centered care, and multidisciplinary treatment planning across stages. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York.

This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Despite triple inhaled therapy, many patients with chronic obstructive pulmonary disease (COPD) continue to experience frequent and severe exacerbations, leading to hospitalizations, symptom burden, and higher mortality risk. In this expert-led discussion, Drs. Diego Maselli and Stephanie Christenson personalized treatment approaches and the role of biologics in advanced COPD care. Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health San Antonio, and Dr. Christenson is an Associate Professor in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine and an attending physician on the Pulmonary Consult Service and in the Pulmonary Clinic at the University of California in San Francisco.

This program is produced in partnership with the American College of Chest Physicians and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.